0
     

Report Added
Report already added
In-Vitro Diagnostics/IVD Market by Product and Service (Instrument, Kits), Technology (Immunoassay, MDx, Hematology, Urinalysis), Application (Diabetes, Oncology, Cardiology, Nephrology, Infectious Diseases) End User (Hospitals) - Global Forecast to 2026

In-Vitro Diagnostics/IVD Market by Product and Service (Instrument, Kits), Technology (Immunoassay, MDx, Hematology, Urinalysis), Application (Diabetes, Oncology, Cardiology, Nephrology, Infectious Diseases) End User (Hospitals) - Global Forecast to 2026

the global IVD market is projected to reach USD 113.1 billion by 2026 from USD 98.2 billion in 2021, at a CAGR of 2.9% during the forecast period. The growth of the IVD market is mainly driven by the rising geriatric population and the subsequent growth in the prevalence of chronic and infectious diseases, increasing adoption of fully automated and POC instruments in developed regions, growing awareness regarding diseases diagnosis in developing regions, and growing R&D investments by industry players to launch new IVD products. Also, the development of disease-specific markers and tests is expected to offer potential growth opportunities to market players in the coming years. However, the unfavorable reimbursement scenario is expected to restrain the growth of this market during the forecast period.

“Reagents & kits segment accounted for the largest share in the IVD market.”

Based on product and service, the IVD market is segmented into reagents & kits, instruments, services, and data management software. The reagents & kits segment accounted for the largest share of 68.1% of the IVD market in 2020. Accessibility to a wide range of reagents and the need for reliable, specific, and faster detection of chronic diseases and genetic disorders in the early stages are expected to drive the growth of this segment.

“Oncology segment is expected to witness the fastest growth in the forecast period.”

Based on application, the IVD market is segmented into infectious diseases, diabetes, Oncology, cardiology, drug testing/ pharmacogenomics, HIV/AIDS, autoimmune diseases, nephrology and other applications. In 2020, infectious diseases accounted for 34.1% of the IVD market. The large share of this segment can be attributed to the rising prevalence of infectious diseases and multi-drug-resistant infectious diseases and the growing need for effective diagnostic tools for these diseases.

However, the oncology segment is projected to grow at the highest CAGR of 6.6% during the forecast period. The increasing number of cancer cases across the globe, the growing demand for personalized medicine, and the availability of funding for cancer research are the major factors driving the market growth.

“Immunoassay/immunochemistry account for the largest share in the IVD market.”

Based on technology, the IVD market is segmented into immunoassay/immunochemistry, clinical chemistry, molecular diagnostics, hematology, microbiology, coagulation and hemostasis, urinalysis and other technologies. The immunoassay/immunochemistry segment accounted for 31% of the IVD technologies market in 2020. The growing preference for these technologies in clinical diagnostics over conventional methods and the ability of immunoassay/immunochemistry technologies to offer faster results with high sensitivity and accuracy are contributing to the growth of this market segment.

“Hospital laboratories accounted for the largest share of IVD market in 2020”

Based on the end user, the IVD market is segmented into hospital laboratories, clinical laboratories, academic institutes, POC (point-of-care) testing centers, patients, and other end users. In 2020, hospital laboratories accounted for the largest share of 47% of the IVD market, followed by clinical laboratories (23.8%) and POC testing centers (13%). Many diagnostic tests are carried out in hospitals. The acquisition of smaller physician practices and groups by hospitals is becoming a noticeable trend in the US healthcare industry; the continuation of this trend will support the IVD market for hospital laboratories.

“North America accounted for the largest share of the IVD market in 2020”

The IVD market is divided into five major regions—North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2020, North America accounted for the largest share of 39.8% of the IVD market, followed by Europe (28%), Asia Pacific (22.9%), Latin America (6.5%), and the Middle East & Africa (2.9%). The IVD market in North America is well established, with the US being the major market in this region. Growth in the North American market is mainly driven by the increasing per capita healthcare expenditure and technologically advanced healthcare infrastructure in the region. Initiatives taken by different government associations are also anticipated to boost market growth in the coming years.

A breakdown of the primary participants (supply-side) for the in vitro diagnostics market referred to for this report is provided below:
•By Company Type: Tier 1–34%, Tier 2–46%, and Tier 3–20%
•By Designation: C-level–35%, Director Level–25%, and Others–40%
•By Region: North America–30%, Europe–45%, Asia Pacific–20%, Latin America- 3%, and Middle East and Africa– 2%
Roche Diagnostics (Switzerland), Siemens Healthineers (Germany), Danaher Corporation (US), Abbott (US), and Thermo Fisher Scientific (US) are the leading players in this market. Other players in this market are Johnson & Johnson (US), Becton, Dickinson and Company (US), Bio-Rad Laboratories (US), Sysmex Corporation (Japan), bioMérieux (France), DiaSorin (Italy), Ortho Clinical Diagnostics (US), and QIAGEN N.V. (Netherlands).

Research Coverage:
The market study covers the in vitro diagnostics market across various segments. It aims at estimating the market size and the growth potential of this market across different segments by product and service, by technology, by application, by end user, and region. The study also includes an in-depth competitive analysis of the key players in the market, along with their company profiles, key observations related to their product and business offerings, recent developments, and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants in this market and provide information regarding the closest approximations of the in vitro diagnostics market and its segments. This report will help stakeholders understand the competitive landscape, gain insights to position their businesses better, and plan suitable go-to-market strategies. The report will also help stakeholders in understanding the pulse of the market and gaining information on key market drivers, restraints, opportunities, and challenges.
Table of Contents

1INTRODUCTION42
1.1OBJECTIVES OF THE STUDY42
1.2MARKET DEFINITION42
1.2.1INCLUSIONS AND EXCLUSIONS42
1.3MARKET SCOPE43
FIGURE 1IN VITRO DIAGNOSTICS MARKET SEGMENTATION43
FIGURE 2IN VITRO DIAGNOSTICS MARKET, BY GEOGRAPHY44
1.4YEARS CONSIDERED FOR THE STUDY44
1.5CURRENCY45
TABLE 1EXCHANGE RATES UTILIZED FOR THE CONVERSION TO USD45
1.6LIMITATIONS45
1.7STAKEHOLDERS45
1.8SUMMARY OF CHANGES45
2RESEARCH METHODOLOGY47
2.1RESEARCH APPROACH47
FIGURE 3RESEARCH DESIGN47
2.1.1SECONDARY RESEARCH48
2.1.1.1Key data from secondary sources49
2.1.2PRIMARY RESEARCH49
2.1.3PRIMARY SOURCES49
FIGURE 4KEY DATA FROM PRIMARY SOURCES50
FIGURE 5KEY INDUSTRY INSIGHTS51
FIGURE 6BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS51
FIGURE 7BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY-SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION52
FIGURE 8BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND-SIDE): BY END USER, DESIGNATION, AND REGION52
2.2MARKET SIZE ESTIMATION53
FIGURE 10REVENUE SHARE ANALYSIS ILLUSTRATION: ROCHE DIAGNOSTICS (2020)54
FIGURE 11SUPPLY-SIDE ANALYSIS: IN VITRO DIAGNOSTICS MARKET (2020)54
FIGURE 13CAGR PROJECTIONS FROM THE ANALYSIS OF MARKET DRIVERS, RESTRAINTS, OPPORTUNITIES & CHALLENGES OF THE IVD INDUSTRY (2021-2026)57
FIGURE 14CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS OF THE IN VITRO DIAGNOSTICS MARKET58
2.3DATA TRIANGULATION APPROACH59
2.4MARKET SHARE ESTIMATION60
2.5ASSUMPTIONS FOR THE STUDY60
2.6LIMITATIONS60
2.6.1METHODOLOGY-RELATED LIMITATIONS60
2.6.2SCOPE-RELATED LIMITATIONS61
2.7RISK ASSESSMENT61
TABLE 2RISK ASSESSMENT: IN VITRO DIAGNOSTICS MARKET61
3EXECUTIVE SUMMARY62
4PREMIUM INSIGHTS66
4.1IN VITRO DIAGNOSTICS MARKET OVERVIEW66
4.2ASIA PACIFIC: IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE AND COUNTRY (2020)67
4.3IN VITRO DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES68
4.4GEOGRAPHIC MIX: IN VITRO DIAGNOSTICS MARKET68
4.5IN VITRO DIAGNOSTICS MARKET: DEVELOPED VS. DEVELOPING MARKETS69
5MARKET OVERVIEW70
5.1INTRODUCTION70
5.2MARKET DYNAMICS70
FIGURE 25IN VITRO DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES70
5.2.1DRIVERS71
5.2.1.1Rising geriatric population and subsequent growth in the prevalence of chronic and infectious diseases71
TABLE 3ESTIMATED INCREASE IN THE GERIATRIC POPULATION, BY REGION (2019–2050)71
FIGURE 26CHINA: NUMBER OF PEOPLE WITH DIABETES MELLITUS, 2000–2045 (IN MILLIONS)72
5.2.1.2Shift from centralized to point-of-care testing72
5.2.1.3Growing awareness and initiatives to increase healthcare accessibility in developing countries72
5.2.1.4Changing technological landscape73
TABLE 4IN VITRO DIAGNOSTICS MARKET: RECENT PRODUCT LAUNCHES73
5.2.2RESTRAINTS74
5.2.2.1Unfavorable reimbursement scenario74
5.2.3OPPORTUNITIES74
5.2.3.1Development of disease-specific biomarkers and tests74
TABLE 5CANCER BIOMARKERS AND USES IN CLINICAL PRACTICE74
5.2.3.2Growing significance of companion diagnostics75
5.2.3.3Growth opportunities in emerging countries75
FIGURE 27ANNUAL PER CAPITA HEALTH EXPENDITURE IN DEVELOPING COUNTRIES, 2019 (USD MILLION)76
5.2.4CHALLENGES76
5.2.4.1Changing regulatory landscape in the EU76
FIGURE 28IVDR: KEY AREAS OF IMPACT77
5.2.4.2Operational barriers faced in conducting diagnostic tests77
6INDUSTRY INSIGHTS78
6.1INDUSTRY TRENDS78
6.1.1AUTOMATION OF CLINICAL LABORATORY TECHNIQUES78
6.1.2MICROFLUIDICS-BASED POC AND LAB-ON-A-CHIP DIAGNOSTIC DEVICES FOR LABORATORY TESTING78
6.1.3GROWING NUMBER OF REAGENT RENTAL AGREEMENTS79
6.2PORTER’S FIVE FORCES ANALYSIS79
TABLE 6PORTER’S FIVE FORCES ANALYSIS: IN VITRO DIAGNOSTICS MARKET79
6.2.1INTENSITY OF COMPETITIVE RIVALRY79
6.2.2BARGAINING POWER OF SUPPLIERS79
6.2.3BARGAINING POWER OF BUYERS80
6.2.4THREAT OF NEW ENTRANTS80
6.2.5THREAT FROM SUBSTITUTES80
6.3REGULATORY ANALYSIS80
6.3.1US80
TABLE 7US: CLASSIFICATION OF IN VITRO DIAGNOSTIC DEVICES80
FIGURE 29US: REGULATORY PROCESS FOR IVD DEVICES81
6.3.2CANADA82
FIGURE 30CANADA: REGULATORY PROCESS FOR IVD DEVICES IN CANADA82
6.3.3EUROPE83
TABLE 8EUROPE: CLASSIFICATION OF IVD DEVICES83
FIGURE 31EUROPE: IVDR TIMELINE83
6.3.4JAPAN84
FIGURE 32REGULATORY PROCESS FOR IVD DEVICES IN JAPAN84
TABLE 9JAPAN: CLASSIFICATION OF IVD REAGENTS84
TABLE 10JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS85
6.3.5CHINA85
TABLE 11CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS85
6.3.6INDIA85
FIGURE 33INDIA: REGULATORY PROCESS FOR IVD DEVICES86
6.3.7INDONESIA86
TABLE 12INDONESIA: REGISTRATION PROCESS FOR IVD DEVICES87
6.3.8RUSSIA87
TABLE 13RUSSIA: CLASSIFICATION OF IVD DEVICES87
6.3.9SAUDI ARABIA88
TABLE 14SAUDI ARABIA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS88
6.3.10MEXICO88
FIGURE 34MEXICO: REGULATORY PROCESS FOR IVD DEVICES88
TABLE 15MEXICO: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS89

6.3.11BRAZIL89
FIGURE 35BRAZIL: REGULATORY PROCESS FOR IVD DEVICES90
6.3.12SOUTH KOREA90
TABLE 16SOUTH KOREA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS90
6.4PATENT ANALYSIS91
FIGURE 36TOP PATENT OWNERS AND APPLICANTS: IN VITRO DIAGNOSTICS MARKET (JANUARY 2011–DECEMBER 2021)91
FIGURE 37PATENT ANALYSIS: IN VITRO DIAGNOSTICS MARKET
(JANUARY 2011–DECEMBER 2021)92
6.5TRADE ANALYSIS92
6.5.1TRADE ANALYSIS FOR DIAGNOSTICS AND LABORATORY REAGENTS92
TABLE 17IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY 2016–2020 (USD MILLION)92
TABLE 18IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY 2016–2020 (TONS)93
6.6ECOSYSTEM ANALYSIS93
FIGURE 38ECOSYSTEM ANALYSIS: IN VITRO DIAGNOSTICS MARKET93
6.7VALUE CHAIN ANALYSIS94
FIGURE 39VALUE CHAIN ANALYSIS: IN VITRO DIAGNOSTICS MARKET94
6.8SUPPLY CHAIN ANALYSIS95
FIGURE 40SUPPLY CHAIN ANALYSIS: IN VITRO DIAGNOSTICS MARKET95
6.9COVID-19 IMPACT ANALYSIS96
6.9.1COVID-19 HEALTH ASSESSMENT96
6.9.2COVID-19 ECONOMIC ASSESSMENT96
6.9.3ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO96
FIGURE 41CRITERIA IMPACTING THE GLOBAL ECONOMY97
6.9.4ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO IN THE IN VITRO DIAGNOSTICS MARKET98
FIGURE 42COVID-19 IMPACT ON GLOBAL IN VITRO DIAGNOSTICS MARKET98
FIGURE 43ROCHE DIAGNOSTICS: IMPACT OF COVID-1999
FIGURE 44ABBOTT LABORATORIES, INC.: IMPACT OF COVID-1999
6.10PRICING ANALYSIS100
TABLE 19AVERAGE SELLING PRICE (USD): IMMUNOASSAY ANALYZERS100
TABLE 20AVERAGE SELLING PRICE (USD): LATERAL FLOW ANALYZERS100
TABLE 21AVERAGE SELLING PRICE (USD): MOLECULAR DIAGNOSTICS100
6.11TECHNOLOGY ANALYSIS101
6.11.1KEY TECHNOLOGIES: IN VITRO DIAGNOSTICS MARKET101
6.11.2ADJACENT TECHNOLOGIES: IN VITRO DIAGNOSTICS MARKET102
6.12ADJACENT MARKET ANALYSIS102
FIGURE 45MICROFLUIDICS MARKET: MARKET OVERVIEW103
6.13CASE STUDY104
FIGURE 46CASE STUDY: MARKET ASSESSMENT AND CONSUMER BUYING BEHAVIOUR IN INDIA104
7IN VITRO DIAGNOSTICS MARKET, BY PRODUCT & SERVICE105
7.1INTRODUCTION106
TABLE 22IVD MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)106
7.2REAGENTS & KITS106
7.2.1TECHNOLOGICAL ADVANCES LIKE RAPID DIAGNOSTICS ARE EXPECTED TO BOOST THE GROWTH OF THIS SEGMENT106
TABLE 23IVD REAGENTS & KITS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)107
TABLE 24IVD REAGENTS & KITS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION)108
7.3INSTRUMENTS108
TABLE 25IVD INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)109
TABLE 26IVD INSTRUMENTS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)109
TABLE 27IVD INSTRUMENTS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)110
7.3.1FULLY AUTOMATED INSTRUMENTS110
7.3.1.1Rising incidence of various diseases and the increasing need to process heavy sample load to drive the market growth110
TABLE 28FULLY AUTOMATED IVD INSTRUMENTS MARKET, BY COUNTRY,
2019–2026 (USD MILLION)111
7.3.2SEMI-AUTOMATED INSTRUMENTS111
7.3.2.1Compact design and cost-effectiveness over automated analyzers are expected to increase the market growth of this segment111
TABLE 29SEMI-AUTOMATED IVD INSTRUMENTS MARKET, BY COUNTRY,
2019–2026 (USD MILLION)112
7.3.3OTHER INSTRUMENTS112
TABLE 30OTHER IVD INSTRUMENTS MARKET, BY COUNTRY,
2019–2026 (USD MILLION)113
7.4DATA MANAGEMENT SOFTWARE113
7.4.1NEED FOR LABORATORY AUTOMATION DRIVES MARKET GROWTH113
TABLE 31KEY DATA MANAGEMENT SOFTWARE SOLUTIONS AVAILABLE IN THE MARKET114
TABLE 32IVD DATA MANAGEMENT SOFTWARE MARKET, BY COUNTRY,
2019–2026 (USD MILLION)115
TABLE 33IVD DATA MANAGEMENT SOFTWARE MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION)115
7.5SERVICES116
7.5.1GROWING COMPETITIVENESS AND THE INCREASING NEED TO OFFER VALUE-ADDED SERVICES TO BOOST THE MARKET GROWTH116
TABLE 34IVD SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)116
TABLE 35IVD SERVICES MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)117
8IN VITRO DIAGNOSTICS MARKET, BY TECHNOLOGY118
8.1INTRODUCTION119
TABLE 36IVD MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)119
8.2IMMUNOASSAY/IMMUNOCHEMISTRY119
TABLE 37IMMUNOASSAY/IMMUNOCHEMISTRY ANALYZERS AVAILABLE
IN THE MARKET120
TABLE 38IVD MARKET FOR IMMUNOASSAY/IMMUNOCHEMISTRY, BY COUNTRY, 2019–2026 (USD MILLION)121
TABLE 39IVD MARKET FOR IMMUNOASSAY/IMMUNOCHEMISTRY, BY TYPE,
2019–2026 (USD MILLION)121
8.2.1ENZYME-LINKED IMMUNOSORBENT ASSAYS122
TABLE 40ELISA ANALYZERS AVAILABLE IN THE MARKET122
TABLE 41ELISA MARKET, BY COUNTRY, 2019–2026 (USD MILLION)123
TABLE 42ELISA MARKET, BY TYPE, 2019–2026 (USD MILLION)124
8.2.1.1Chemiluminescence immunoassays124
8.2.1.1.1CLIAs hold the largest share of the ELISA market124
TABLE 43CHEMILUMINESCENCE IMMUNOASSAY SYSTEMS AVAILABLE IN THE MARKET124
TABLE 44CHEMILUMINESCENCE IMMUNOASSAYS MARKET, BY COUNTRY,
2019–2026 (USD MILLION)125
8.2.1.2Fluorescence immunoassays126
8.2.1.2.1Rapid processing, high sensitivity, and low cost have driven the adoption of FIAs126
TABLE 45FLUORESCENCE IMMUNOASSAY SYSTEMS AVAILABLE IN THE MARKET126
TABLE 46FLUORESCENCE IMMUNOASSAYS MARKET, BY COUNTRY,
2019–2026 (USD MILLION)127
8.2.1.3Colorimetric immunoassays127
8.2.1.3.1Despite widespread use, demand for colorimetric immunoassays has declined due to low sensitivity127
TABLE 47COLORIMETRIC IMMUNOASSAY SYSTEMS AVAILABLE IN THE MARKET128
TABLE 48COLORIMETRIC IMMUNOASSAYS MARKET, BY COUNTRY,
2019–2026 (USD MILLION)128
8.2.2RADIOIMMUNOASSAYS129
8.2.2.1Small sample volumes, rapid processing times offset by high cost and potential health hazards129
TABLE 49RADIOIMMUNOASSAYS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)129
8.2.3RAPID TESTS130
8.2.3.1COVID-19 pandemic drove demand for rapid tests130
TABLE 50RAPID TESTS AVAILABLE IN THE MARKET130
TABLE 51RAPID TESTS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)131
8.2.4WESTERN BLOTTING131
8.2.4.1Western blotting is the gold standard for result validation131
TABLE 52WESTERN BLOTTING SYSTEMS AVAILABLE IN THE MARKET132
TABLE 53WESTERN BLOTTING MARKET, BY COUNTRY, 2019–2026 (USD MILLION)132
8.2.5ENZYME-LINKED IMMUNOSPOT ASSAYS133
8.2.5.1High sensitivity, functionality, and adaptability support the growth of ELISPOT133
TABLE 54ELISPOT ASSAYS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)133
8.3CLINICAL CHEMISTRY134
TABLE 55CLINICAL CHEMISTRY ANALYZERS FOR HIGH AND MID-VOLUME LABORATORIES134
TABLE 56CLINICAL CHEMISTRY ANALYZERS FOR LOW-VOLUME LABORATORIES135
TABLE 57BLOOD GAS ANALYZERS AVAILABLE IN THE MARKET136
TABLE 58IVD MARKET FOR CLINICAL CHEMISTRY, BY COUNTRY,
2019–2026 (USD MILLION)137
TABLE 59CLINICAL CHEMISTRY MARKET, BY TYPE, 2019–2026 (USD MILLION)137
8.3.1BASIC METABOLIC PANELS138
8.3.1.1Basic metabolic panels hold the largest share of the clinical chemistry market138
TABLE 60BASIC METABOLIC PANELS MARKET, BY COUNTRY,
2019–2026 (USD MILLION)138
8.3.2LIVER PANELS139
8.3.2.1Growing liver disease burden and alcohol consumption driving market growth139
TABLE 61LIVER PANELS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)139
8.3.3RENAL PROFILES140
8.3.3.1Rising kidney disease prevalence ensures demand for renal profiles140
TABLE 62RENAL PROFILES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)140
8.3.4LIPID PROFILES141
8.3.4.1Growth in CVD caseload supports the adoption of lipid panels141
TABLE 63LIPID PROFILES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)141
8.3.5THYROID FUNCTION PANELS142
8.3.5.1Rising awareness and incidence of thyroid diseases drive the market142
TABLE 64THYROID FUNCTION PANELS MARKET, BY COUNTRY,
2019–2026 (USD MILLION)142
8.3.6ELECTROLYTE PANELS143
8.3.6.1Focus on preventive healthcare to favor the market for electrolyte panels143
TABLE 65ELECTROLYTE PANELS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)143
8.3.7SPECIALTY CHEMICAL TESTS144
8.3.7.1Includes tests not prescribed regularly, such as protein tests, drugs-of-abuse tests, and therapeutic drug monitoring144
TABLE 66SPECIALTY CHEMICAL TESTS MARKET, BY COUNTRY,
2019–2026 (USD MILLION)144
8.4MOLECULAR DIAGNOSTICS145
TABLE 67AUTOMATED MOLECULAR DIAGNOSTIC PLATFORMS AVAILABLE IN THE MARKET145
TABLE 68IVD MARKET FOR MOLECULAR DIAGNOSTICS, BY COUNTRY,
2019–2026 (USD MILLION)146
TABLE 69MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION)147
8.4.1POLYMERASE CHAIN REACTION147
8.4.1.1PCR dominates the molecular diagnostics market147
TABLE 70PCR INSTRUMENTS AVAILABLE IN THE MARKET147
TABLE 71PCR MARKET, BY COUNTRY, 2019–2026 (USD MILLION)148
8.4.2ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY148
8.4.2.1Growing popularity of INAAT and NAAT for infectious disease diagnostics to support market growth148
TABLE 72INAAT MARKET, BY COUNTRY, 2019–2026 (USD MILLION)149
8.4.3HYBRIDIZATION150
8.4.3.1Advanced in hybridization and automation have driven the adoption of hybridization technologies150
TABLE 73HYBRIDIZATION MARKET, BY COUNTRY, 2019–2026 (USD MILLION)150
8.4.4DNA SEQUENCING & NEXT-GENERATION SEQUENCING151
8.4.4.1Growing use in personalized medicine and declining costs151
TABLE 74NGS INSTRUMENTS AVAILABLE IN THE MARKET151
TABLE 75DNA SEQUENCING & NGS MARKET, BY COUNTRY,
2019–2026 (USD MILLION)152
8.4.5MICROARRAYS152
8.4.5.1Advantages of microarrays—high throughput, resolution, and sensitivity—drive their adoption152
TABLE 76MICROARRAYS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)153
8.4.6OTHER MDX TECHNOLOGIES154
TABLE 77OTHER MOLECULAR DIAGNOSTIC TECHNOLOGIES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)154
8.5HEMATOLOGY155
8.5.1INCREASING ADOPTION OF AUTOMATED HEMATOLOGY ANALYZERS IS EXPECTED TO DRIVE THE MARKET GROWTH155
TABLE 78HEMATOLOGY ANALYZERS AVAILABLE IN THE MARKET155
TABLE 79IVD MARKET FOR HEMATOLOGY, BY COUNTRY, 2019–2026 (USD MILLION)156
8.6MICROBIOLOGY157
8.6.1RISING PREVALENCE OF INFECTIOUS DISEASES WILL BOOST THE GROWTH OF THIS SEGMENT157
TABLE 80MICROBIOLOGY INSTRUMENTS AVAILABLE IN THE MARKET157
TABLE 81IVD MARKET FOR MICROBIOLOGY, BY COUNTRY, 2019–2026 (USD MILLION)158
8.7COAGULATION & HEMOSTASIS158
8.7.1INCREASING NUMBER OF SURGERIES AND GROWING USE OF ANTICOAGULATION THERAPY WILL DRIVE THE MARKET GROWTH FOR THIS SEGMENT158
TABLE 82COAGULATION ANALYZERS AVAILABLE IN THE MARKET159
TABLE 83POINT-OF-CARE/SELF-MONITORING COAGULATION ANALYZERS AVAILABLE IN THE MARKET160
TABLE 84IVD MARKET FOR COAGULATION & HEMOSTASIS, BY COUNTRY,
2019–2026 (USD MILLION)160
8.8URINALYSIS161
8.8.1RISING PREVALENCE OF DIABETES AND KIDNEY DISORDERS WILL HAVE A POSITIVE IMPACT ON THE GROWTH OF THIS SEGMENT161
TABLE 85URINALYSIS INSTRUMENTS AVAILABLE IN THE MARKET161
TABLE 86IVD MARKET FOR URINALYSIS, BY COUNTRY, 2019–2026 (USD MILLION)162
8.9OTHER TECHNOLOGIES162
TABLE 87BLOOD GLUCOSE TESTING SYSTEMS AVAILABLE IN THE MARKET163
TABLE 88TISSUE PROCESSORS, EMBEDDERS, MICROTOMES, AND STAINERS AVAILABLE IN THE MARKET163
TABLE 89IVD MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY,
2019–2026 (USD MILLION)164
9IN VITRO DIAGNOSTICS MARKET, BY APPLICATION165
9.1INTRODUCTION166
TABLE 90IVD MARKET, BY APPLICATION, 2019–2026 (USD MILLION)166
9.2INFECTIOUS DISEASES166
9.2.1INFECTIOUS DISEASES ACCOUNTED FOR THE LARGEST MARKET
SHARE IN 2020166
TABLE 91IVD MARKET FOR INFECTIOUS DISEASES, BY COUNTRY,
2019–2026 (USD MILLION)167
9.3DIABETES167
9.3.1DIABETES PATIENTS REQUIRE CONSTANT MONITORING167
TABLE 92GLOBAL DIABETIC PATIENT POPULATION, 2019 VS. 2030 (MILLION)168
TABLE 93IVD MARKET FOR DIABETES, BY COUNTRY, 2019–2026 (USD MILLION)168
9.4ONCOLOGY169
9.4.1ADVANCEMENTS IN MOLECULAR DIAGNOSTICS WILL AID THE EARLY DIAGNOSIS OF CANCER169
TABLE 94IVD MARKET FOR ONCOLOGY, BY COUNTRY, 2019–2026 (USD MILLION)170
9.5CARDIOLOGY170
9.5.1INCREASING DISEASE BURGEN OF CVD TO DRIVE THE MARKET GROWTH170
TABLE 95IVD MARKET FOR CARDIOLOGY, BY COUNTRY, 2019–2026 (USD MILLION)170
9.6DRUG TESTING/PHARMACOGENOMICS171
9.6.1INCREASING CONSUMPTION OF ILLICIT DRUGS WILL LEAD TO AN INCREASE IN TOXICOLOGY TESTING171
TABLE 96IVD MARKET FOR DRUG TESTING/PHARMACOGENOMICS, BY COUNTRY, 2019–2026 (USD MILLION)172
9.7HIV/AIDS172
9.7.1HIGH PREVALENCE OF AIDS IS EXPECTED TO BOOST THE MARKET GROWTH172
TABLE 97IVD MARKET FOR HIV/AIDS, BY COUNTRY, 2019–2026 (USD MILLION)173
9.8AUTOIMMUNE DISEASES173
9.8.1DEVELOPMENT OF NOVEL DISEASE-SPECIFIC BIOMARKERS WILL HAVE A POSITIVE IMPACT ON THE MARKET GROWTH173
TABLE 98IVD MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY,
2019–2026 (USD MILLION)174
9.9NEPHROLOGY174
9.9.1INCREASING PREVALENCE OF CHRONIC KIDNEY DISEASES IS EXPECTED TO DRIVE THE MARKET GROWTH FOR THIS SEGMENT174
TABLE 99IVD MARKET FOR NEPHROLOGY, BY COUNTRY, 2019–2026 (USD MILLION)175
9.10OTHER APPLICATIONS175
9.10.1INCREASING DEMAND FOR SELF-MONITORING KITS IS LIKELY TO HAVE A POSITIVE IMPACT ON THE MARKET GROWTH175
TABLE 100IVD MARKET FOR OTHER APPLICATIONS, BY COUNTRY,
2019–2026 (USD MILLION)176

10IN VITRO DIAGNOSTICS MARKET, BY END USER177
10.1INTRODUCTION178
TABLE 101IVD MARKET, BY END USER, 2019–2026 (USD MILLION)178
10.2HOSPITAL LABORATORIES178
10.2.1GROWING PATIENT POPULATION AND REIMBURSEMENT POLICIES FOR DIAGNOSTIC TESTS WILL DRIVE THE MARKET GROWTH178
TABLE 102IVD MARKET FOR HOSPITAL LABORATORIES, BY COUNTRY,
2019–2026 (USD MILLION)179
10.3CLINICAL LABORATORIES179
TABLE 103IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE,
2019–2026 (USD MILLION)180
TABLE 104IVD MARKET FOR CLINICAL LABORATORIES, BY COUNTRY
2019–2026 (USD MILLION)180
10.3.1LARGE/REFERENCE LABORATORIES181
10.3.1.1Rising infectious disease burden and demand for larger testing capacities will drive the growth of this segment181
TABLE 105LARGE/REFERENCE LABORATORIES MARKET, BY COUNTRY,
2019–2026 (USD MILLION)181
10.3.2MEDIUM-SIZED LABORATORIES182
10.3.2.1Increasing use of automated instruments to drive market growth182
TABLE 106MEDIUM-SIZED LABORATORIES MARKET, BY COUNTRY,
2019–2026 (USD MILLION)182
10.3.3SMALL LABORATORIES182
10.3.3.1Increasing adoption of semi-automated instruments and low-end point-of-care devices will boost segment growth182
TABLE 107SMALL LABORATORIES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)183
10.4POINT-OF-CARE TESTING CENTERS183
10.4.1GROWING USE OF POC DEVICES IN HOSPITALS AND CLINICAL LABORATORIES IS EXPECTED TO PROPEL THE GROWTH OF THIS SEGMENT183
TABLE 108IVD MARKET FOR POINT-OF-CARE TESTING CENTERS, BY COUNTRY,
2019–2026 (USD MILLION)184
10.5PATIENTS184
10.5.1INCREASING ADOPTION OF PATIENT SELF-TESTING KITS TO DRIVE THE MARKET GROWTH184
TABLE 109IVD MARKET FOR PATIENTS, BY COUNTRY, 2019–2026 (USD MILLION)185
10.6ACADEMIC INSTITUTES185
10.6.1INCREASING INDUSTRY-ACADEMIA COLLABORATIONS FOR PRODUCT DEVELOPMENT SUPPORTS MARKET GROWTH185
TABLE 110IVD MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY,
2019–2026 (USD MILLION)186
10.7OTHER END USERS186
TABLE 111IVD MARKET FOR OTHER END USERS, BY COUNTRY,
2019–2026 (USD MILLION)187

11IN VITRO DIAGNOSTICS MARKET, BY REGION188
11.1INTRODUCTION189
TABLE 112IVD MARKET, BY REGION, 2019–2026 (USD MILLION)189
11.2NORTH AMERICA189
FIGURE 47NORTH AMERICA: IVD MARKET SNAPSHOT190
TABLE 113NORTH AMERICA: IVD MARKET, BY COUNTRY, 2019–2026 (USD MILLION)190
TABLE 114NORTH AMERICA: IVD MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION)191
TABLE 115NORTH AMERICA: IVD INSTRUMENTS MARKET, BY TYPE,
2019–2026 (USD MILLION)191
TABLE 116NORTH AMERICA: IVD MARKET, BY APPLICATION,
2019–2026 (USD MILLION)191
TABLE 117NORTH AMERICA: IVD MARKET, BY TECHNOLOGY,
2019–2026 (USD MILLION)192
TABLE 118NORTH AMERICA: IVD MARKET, BY END USER, 2019–2026 (USD MILLION)192
TABLE 119NORTH AMERICA: IVD MARKET FOR CLINICAL LABORATORIES,
BY TYPE, 2019–2026 (USD MILLION)193
11.2.1US193
11.2.1.1The US dominates the North American Market193
TABLE 120US: MACROECONOMIC INDICATORS194
TABLE 121US: IVD MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)194
TABLE 122US: IVD INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)194
TABLE 123US: IVD MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)195
TABLE 124US: IVD MARKET, BY APPLICATION, 2019–2026 (USD MILLION)195
TABLE 125US: IVD MARKET, BY END USER, 2019–2026 (USD MILLION)196
TABLE 126US: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE,
2019–2026 (USD MILLION)196
11.2.2CANADA196
11.2.2.1Increasing prevalence of chronic illness and implementation of favorable government initiatives drive the market in Canada196
TABLE 127CANADA: ESTIMATED PREVALENCE OF DIABETES197
TABLE 128CANADA: MACROECONOMIC INDICATORS197
TABLE 129CANADA: IVD MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)198
TABLE 130CANADA: IVD INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)198
TABLE 131CANADA: IVD MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)198
TABLE 132CANADA: IVD MARKET, BY APPLICATION, 2019–2026 (USD MILLION)199
TABLE 133CANADA: IVD MARKET, BY END USER, 2019–2026 (USD MILLION)199
TABLE 134CANADA: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE,
2019–2026 (USD MILLION)200
11.3EUROPE200
TABLE 135EUROPE: IVD MARKET, BY COUNTRY, 2019–2026 (USD MILLION)201
TABLE 136EUROPE: IVD MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)201
TABLE 137EUROPE: IVD INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)202
TABLE 138EUROPE: IVD MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)202
TABLE 139EUROPE: IVD MARKET, BY APPLICATION, 2019–2026 (USD MILLION)203
TABLE 140EUROPE: IVD MARKET, BY END USER, 2019–2026 (USD MILLION)203
TABLE 141EUROPE: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE,
2019–2026 (USD MILLION)203
11.3.1GERMANY204
11.3.1.1Increasing healthcare expenditure to drive the market growth in Germany204
TABLE 142GERMANY: MACROECONOMIC INDICATORS204
TABLE 143GERMANY: IVD MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)204
TABLE 144GERMANY: IVD INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)205
TABLE 145GERMANY: IVD MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)205
TABLE 146GERMANY: IVD MARKET, BY APPLICATION, 2019–2026 (USD MILLION)206
TABLE 147GERMANY: IVD MARKET, BY END USER, 2019–2026 (USD MILLION)206
TABLE 148GERMANY: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE,
2019–2026 (USD MILLION)207
11.3.2FRANCE207
11.3.2.1Rising R&D Expenditure in France to drive market growth207
TABLE 149FRANCE: MACROECONOMIC INDICATORS207
TABLE 150FRANCE: IVD MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)208
TABLE 151FRANCE: IVD INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)208
TABLE 152FRANCE: IVD MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)208
TABLE 153FRANCE: IVD MARKET, BY APPLICATION, 2019–2026 (USD MILLION)209
TABLE 154FRANCE: IVD MARKET, BY END USER, 2019–2026 (USD MILLION)209
TABLE 155FRANCE: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE,
2019–2026 (USD MILLION)210
11.3.3UK210
11.3.3.1The increasing number of accredited diagnostic laboratories propels market growth for in vitro diagnostics in the UK210
TABLE 156UK: MACROECONOMIC INDICATORS211
TABLE 157UK: IVD MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)211
TABLE 158UK: IVD INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)211
TABLE 159UK: IVD MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)212
TABLE 160UK: IVD MARKET, BY APPLICATION, 2019–2026 (USD MILLION)212
TABLE 161UK: IVD MARKET, BY END USER, 2019–2026 (USD MILLION)213
TABLE 162UK: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE,
2019–2026 (USD MILLION)213
11.3.4ITALY213
11.3.4.1Adoption of advanced diagnostic technologies to drive market growth in Italy213
TABLE 163ITALY: MACROECONOMIC INDICATORS214
TABLE 164ITALY: IVD MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)214
TABLE 165ITALY: IVD INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)214
TABLE 166ITALY: IVD MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)215
TABLE 167ITALY: IVD MARKET, BY APPLICATION, 2019–2026 (USD MILLION)215
TABLE 168ITALY: IVD MARKET, BY END USER, 2019–2026 (USD MILLION)216
TABLE 169ITALY: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE,
2019–2026 (USD MILLION)216
11.3.5SPAIN216
11.3.5.1Growth of the geriatric population and rising demand for testing support the market in Spain216
TABLE 170SPAIN: MACROECONOMIC INDICATORS217
TABLE 171SPAIN: IVD MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)217
TABLE 172SPAIN: IVD INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)217
TABLE 173SPAIN: IVD MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)218
TABLE 174SPAIN: IVD MARKET, BY APPLICATION, 2019–2026 (USD MILLION)218
TABLE 175SPAIN: IVD MARKET, BY END USER, 2019–2026 (USD MILLION)219
TABLE 176SPAIN: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE,
2019–2026 (USD MILLION)219
11.3.6RUSSIA219
11.3.6.1Increasing access to quality healthcare will support market growth in Russia219
TABLE 177RUSSIA: MACROECONOMIC INDICATORS220
TABLE 178RUSSIA: IVD MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)220
TABLE 179RUSSIA: IVD INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)220
TABLE 180RUSSIA: IVD MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)221
TABLE 181RUSSIA: IVD MARKET, BY APPLICATION, 2019–2026 (USD MILLION)221
TABLE 182RUSSIA: IVD MARKET, BY END USER, 2019–2026 (USD MILLION)222
TABLE 183RUSSIA: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE,
2019–2026 (USD MILLION)222
11.3.7REST OF EUROPE222
TABLE 184ROE: IVD MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)223
TABLE 185ROE: IVD INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)223
TABLE 186ROE: IVD MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)223
TABLE 187ROE: IVD MARKET, BY APPLICATION, 2019–2026 (USD MILLION)224
TABLE 188ROE: IVD MARKET, BY END USER, 2019–2026 (USD MILLION)224
TABLE 189ROE: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE,
2019–2026 (USD MILLION)225
11.4ASIA PACIFIC225
FIGURE 48ASIA PACIFIC: IVD MARKET SNAPSHOT226
TABLE 190ASIA PACIFIC: IVD MARKET, BY COUNTRY, 2019–2026 (USD MILLION)227
TABLE 191ASIA PACIFIC: IVD MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION)227
TABLE 192ASIA PACIFIC: IVD INSTRUMENTS MARKET, BY TYPE,
2019–2026 (USD MILLION)227
TABLE 193ASIA PACIFIC: IVD MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)228
TABLE 194ASIA PACIFIC: IVD MARKET, BY APPLICATION, 2019–2026 (USD MILLION)229
TABLE 195ASIA PACIFIC: IVD MARKET, BY END USER, 2019–2026 (USD MILLION)229
TABLE 196ASIA PACIFIC: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE,
2019–2026 (USD MILLION)230
11.4.1JAPAN230
11.4.1.1Universal healthcare reimbursement policy to drive market
growth in Japan230
TABLE 197JAPAN: MACROECONOMIC INDICATORS231
TABLE 198JAPAN: IVD MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)231
TABLE 199JAPAN: IVD INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)231
TABLE 200JAPAN: IVD MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)232
TABLE 201JAPAN: IVD MARKET, BY APPLICATION, 2019–2026 (USD MILLION)232
TABLE 202JAPAN: IVD MARKET, BY END USER, 2019–2026 (USD MILLION)233
TABLE 203JAPAN: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE,
2019–2026 (USD MILLION)233
11.4.2CHINA233
11.4.2.1Growing public access to modern healthcare and the outbreak of COVID-19 to drive market growth233
TABLE 204CHINA: MACROECONOMIC INDICATORS234
TABLE 205CHINA: IVD MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)234
TABLE 206CHINA: IVD INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)234
TABLE 207CHINA: IVD MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)235
TABLE 208CHINA: IVD MARKET, BY APPLICATION, 2019–2026 (USD MILLION)235
TABLE 209CHINA: IVD MARKET, BY END USER, 2019–2026 (USD MILLION)236
TABLE 210CHINA: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE,
2019–2026 (USD MILLION)236
11.4.3INDIA236
11.4.3.1Increasing private & public investments in the country’s healthcare system will drive market growth236
TABLE 211INDIA: MACROECONOMIC INDICATORS237
TABLE 212INDIA: IVD MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)237
TABLE 213INDIA: IVD INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)237
TABLE 214INDIA: IVD MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)238
TABLE 215INDIA: IVD MARKET, BY APPLICATION, 2019–2026 (USD MILLION)238
TABLE 216INDIA: IVD MARKET, BY END USER, 2019–2026 (USD MILLION)239
TABLE 217INDIA: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE,
2019–2026 (USD MILLION)239
11.4.4SOUTH KOREA239
11.4.4.1Increased geriatric population coupled with a parallel increase in chronic illnesses to drive the market growth239
TABLE 218SOUTH KOREA: MACROECONOMIC INDICATORS240
TABLE 219SOUTH KOREA: IVD MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION)240
TABLE 220SOUTH KOREA: IVD INSTRUMENTS MARKET, BY TYPE,
2019–2026 (USD MILLION)240
TABLE 221SOUTH KOREA: IVD MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)241
TABLE 222SOUTH KOREA: IVD MARKET, BY APPLICATION, 2019–2026 (USD MILLION)241
TABLE 223SOUTH KOREA: IVD MARKET, BY END USER, 2019–2026 (USD MILLION)242
TABLE 224SOUTH KOREA: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE,
2019–2026 (USD MILLION)242
11.4.5INDONESIA242
11.4.5.1Increasing insurance penetration and rising burden of infectious diseases to drive market growth242
TABLE 225INDONESIA: MACROECONOMIC INDICATORS243
TABLE 226INDONESIA: IVD MARKET, BY PRODUCT & SERVICE,
2019–2026 (USD MILLION)243
TABLE 227INDONESIA: IVD INSTRUMENTS MARKET, BY TYPE,
2019–2026 (USD MILLION)243
TABLE 228INDONESIA: IVD MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)244
TABLE 229INDONESIA: IVD MARKET, BY APPLICATION, 2019–2026 (USD MILLION)244
TABLE 230INDONESIA: IVD MARKET, BY END USER, 2019–2026 (USD MILLION)245
TABLE 231INDONESIA: IVD MARKET FOR CLINICAL LABORATORIES, BY TYPE,
2019–2026 (USD MILLION)245
11.4.6REST OF ASIA PACIFIC245
TABLE 232ROAPAC: IVD MARKET, BY PRODUCT & SERVICE, 2019–2026 (USD MILLION)246
TABLE 233ROAPAC: IVD INSTRUMENTS MARKET, BY TYPE, 2019–2026 (USD MILLION)246
TABLE 234ROAPAC: IVD MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)246
TABLE 235ROAPAC: IVD MARKET, BY APPLICATION, 2019–2026 (USD M

Report Title: In-Vitro Diagnostics/IVD Market by Product and Service (Instrument, Kits), Technology (Immunoassay, MDx, Hematology, Urinalysis), Application (Diabetes, Oncology, Cardiology, Nephrology, Infectious Diseases) End User (Hospitals) - Global Forecast to 2026


Your Details
Valid Invalid number

SELECT A FORMAT

ADD TO CART BUY NOW

Related Report

2022 What's Next for Vietnam Diagnostics Market?-- Supplier Shares, Strategies, Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2022 What's Next for Vietnam Diagnostics Market?-- Supplier Shares, Strategies, Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2022 What's Next for Venezuela Diagnostics Market?-- Supplier Shares, Strategies, Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2022 What's Next for Venezuela Diagnostics Market?-- Supplier Shares, Strategies, Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2022 What's Next for US Diagnostics Market?-- Supplier Shares, Strategies, Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2022 What's Next for US Diagnostics Market?-- Supplier Shares, Strategies, Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2022 What's Next for Uruguay Diagnostics Market?-- Supplier Shares, Strategies, Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2022 What's Next for Uruguay Diagnostics Market?-- Supplier Shares, Strategies, Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2022 What's Next for United Arab Emirates Diagnostics Market?-- Supplier Shares, Strategies, Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2022 What's Next for United Arab Emirates Diagnostics Market?-- Supplier Shares, Strategies, Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2022 What's Next for Ukraine Diagnostics Market?-- Supplier Shares, Strategies, Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM

2022 What's Next for Ukraine Diagnostics Market?-- Supplier Shares, Strategies, Volume and Sales Forecasts for 500 Tests--Blood Banking, Cancer Diagnostics, Clinical Chemistry, Coagulation, Drugs of Abuse, Endocrine Function, Flow Cytometry, Hematology, Immunoproteins, Infectious Diseases, Molecular Diagnostics, TDM